Roger D. Tung

3.2k total citations
41 papers, 2.0k citations indexed

About

Roger D. Tung is a scholar working on Infectious Diseases, Virology and Molecular Biology. According to data from OpenAlex, Roger D. Tung has authored 41 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Infectious Diseases, 15 papers in Virology and 14 papers in Molecular Biology. Recurrent topics in Roger D. Tung's work include HIV/AIDS drug development and treatment (17 papers), HIV Research and Treatment (15 papers) and Hepatitis C virus research (8 papers). Roger D. Tung is often cited by papers focused on HIV/AIDS drug development and treatment (17 papers), HIV Research and Treatment (15 papers) and Hepatitis C virus research (8 papers). Roger D. Tung collaborates with scholars based in United States, Malaysia and Sweden. Roger D. Tung's co-authors include Daniel H. Rich, Christopher Baker, B. Govinda Rao, Mark A. Murcko, Manuel A. Navia, Scott L. Harbeson, Eric R. Olson, Fredrick Van Goor, T. J. Neuberger and Kimberly Straley and has published in prestigious journals such as Journal of the American Chemical Society, Blood and The Journal of Immunology.

In The Last Decade

Roger D. Tung

41 papers receiving 1.9k citations

Peers

Roger D. Tung
Krishna C. Agrawal United States
Terry A. Lyle United States
Melissa S. Egbertson United States
Jerome P. Horwitz United States
Tino W. Sanchez United States
Victor G. Matassa Italy
Bhasker V. Shetty United States
Brian M. McKeever United States
Paul A. Aristoff United States
Stephen Castellino United States
Krishna C. Agrawal United States
Roger D. Tung
Citations per year, relative to Roger D. Tung Roger D. Tung (= 1×) peers Krishna C. Agrawal

Countries citing papers authored by Roger D. Tung

Since Specialization
Citations

This map shows the geographic impact of Roger D. Tung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger D. Tung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger D. Tung more than expected).

Fields of papers citing papers by Roger D. Tung

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roger D. Tung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger D. Tung. The network helps show where Roger D. Tung may publish in the future.

Co-authorship network of co-authors of Roger D. Tung

This figure shows the co-authorship network connecting the top 25 collaborators of Roger D. Tung. A scholar is included among the top collaborators of Roger D. Tung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roger D. Tung. Roger D. Tung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Harbeson, Scott L., Adam J. Morgan, Ara M. Aslanian, et al.. (2017). Altering Metabolic Profiles of Drugs by Precision Deuteration 2: Discovery of a Deuterated Analog of Ivacaftor with Differentiated Pharmacokinetics for Clinical Development. Journal of Pharmacology and Experimental Therapeutics. 362(2). 359–367. 54 indexed citations
2.
Uttamsingh, Vinita, Richard Gallegos, Scott L. Harbeson, et al.. (2015). Altering Metabolic Profiles of Drugs by Precision Deuteration: Reducing Mechanism-Based Inhibition of CYP2D6 by Paroxetine. Journal of Pharmacology and Experimental Therapeutics. 354(1). 43–54. 35 indexed citations
3.
4.
Miller, John F., C. Webster Andrews, Eric S. Furfine, et al.. (2006). Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: The discovery of GW0385. Bioorganic & Medicinal Chemistry Letters. 16(7). 1788–1794. 70 indexed citations
5.
Perni, Robert B., J. PITLIK, John J. Court, et al.. (2004). Inhibitors of hepatitis C virus NS3·4A protease 2. Warhead SAR and optimization. Bioorganic & Medicinal Chemistry Letters. 14(6). 1441–1446. 41 indexed citations
6.
Perni, Robert B., Lawrence F. Courtney, David D. Deininger, et al.. (2003). Inhibitors of hepatitis C virus NS3·4A protease 1. Non-Charged tetrapeptide variants. Bioorganic & Medicinal Chemistry Letters. 13(22). 4059–4063. 25 indexed citations
7.
Gulick, Roy M., Laura Smeaton, Richard T. D'Aquila, et al.. (2001). Indinavir, Nevirapine, Stavudine, and Lamivudine for Human Immunodeficiency Virus–Infected, Amprenavir‐Experienced Subjects: AIDS Clinical Trials Group Protocol 373. The Journal of Infectious Diseases. 183(5). 715–721. 9 indexed citations
8.
9.
Murphy, Robert L., Roy M. Gulick, Victor DeGruttola, et al.. (1999). Treatment with Amprenavir Alone or Amprenavir with Zidovudine and Lamivudine in Adults with Human Immunodeficiency Virus Infection. The Journal of Infectious Diseases. 179(4). 808–816. 69 indexed citations
10.
Decker, Caroline J., et al.. (1998). Metabolism of Amprenavir in Liver Microsomes: Role of CYP3A4 Inhibition for Drug Interactions. Journal of Pharmaceutical Sciences. 87(7). 803–807. 92 indexed citations
11.
Baker, Christopher, Francesco G. Salituro, John J. Court, et al.. (1998). Design, synthesis, and conformational analysis of a novel series of HIV protease inhibitors. Bioorganic & Medicinal Chemistry Letters. 8(24). 3631–3636. 15 indexed citations
12.
Pazhanisamy, S., et al.. (1995). Weak Binding of VX-478 to Human Plasma Proteins and Implications for Anti-Human Immunodeficiency Virus Therapy. The Journal of Infectious Diseases. 172(5). 1238–1245. 63 indexed citations
13.
Armistead, David M., Michael C. Badia, David D. Deininger, et al.. (1995). Design, synthesis and structure of non-macrocyclic inhibitors of FKBP12, the major binding protein for the immunosuppressant FK506. Acta Crystallographica Section D Biological Crystallography. 51(4). 522–528. 52 indexed citations
14.
Nelson, P., Akinori Kawamura, Michael Su, et al.. (1993). Immunosuppressive activity of [MeBm2t]1-, D-diaminobutyryl-8-, and D-diaminopropyl-8-cyclosporin analogues correlates with inhibition of calcineurin phosphatase activity. The Journal of Immunology. 150(6). 2139–2147. 36 indexed citations
15.
Williams, Peter, Mark G. Bock, Roger D. Tung, et al.. (1992). Development of a novel class of cyclic hexapeptide oxytocin antagonists based on a natural product. Journal of Medicinal Chemistry. 35(21). 3905–3918. 28 indexed citations
16.
Colucci, William J., et al.. (1990). Synthesis of D-lysine8-cyclosporine A. Further characterization of BOP-Cl in the 2-7 hexapeptide fragment synthesis. The Journal of Organic Chemistry. 55(9). 2895–2903. 45 indexed citations
17.
Pettibone, Douglas J., Bradley V. Clineschmidt, Edward V. Lis, et al.. (1990). In vitro pharmacological profile of a novel structural class of oxytocin antagonists.. Journal of Pharmacology and Experimental Therapeutics. 256(1). 304–308. 18 indexed citations
18.
Tung, Roger D. & Daniel H. Rich. (1987). Total synthesis of the unusual cyclosporine amino acid MeBMT. Tetrahedron Letters. 28(11). 1139–1142. 30 indexed citations
19.
Cushman, David W., et al.. (1983). Purification and characterization of enkephalinase, angiotensin converting enzyme, and a third peptidyldipeptidase from rat brain. Life Sciences. 33. 25–28. 12 indexed citations
20.
Tung, Roger D., et al.. (1974). Kinetics of protonation of Li+, Na+ and K+ salts of anthracenide radical ions in DME and THF by methanol and tert -butanol; the significant contribution of the encounter complex to the protonation. Proceedings of the Royal Society of London A Mathematical and Physical Sciences. 339(1619). 417–433. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Krishna C. Agrawal Breakdown of academic impact, for papers by Terry A. Lyle Breakdown of academic impact, for papers by Melissa S. Egbertson Breakdown of academic impact, for papers by Jerome P. Horwitz Breakdown of academic impact, for papers by Tino W. Sanchez Breakdown of academic impact, for papers by Victor G. Matassa Breakdown of academic impact, for papers by Bhasker V. Shetty Breakdown of academic impact, for papers by Brian M. McKeever Breakdown of academic impact, for papers by Paul A. Aristoff Breakdown of academic impact, for papers by Stephen Castellino
Rankless by CCL
2026